GH vs CAI vs GRAL Stock Comparison

Guardant Health, Caris Life Sciences and Grail Prices as of Nov 13, 2026 Peers: Industry group
GH Guardant Health, Inc.
$151.70 -6.9% 1M +61.2% 1Y
Market cap
$19.56B
P/E
–
Revenue (TTM)
$1.28B
Div. yield
–
Diagnostic Labs Healthcare
3 wins
GRAL GRAIL, Inc.
$115.89 -17.0% 1M +39.3% 1Y
Market cap
$5.04B
P/E
–
Revenue (TTM)
$159.20M
Div. yield
–
Diagnostic Labs Healthcare

Head to Head

6 decided of 12

Guardant Health leads on 3 of the 12 questions below (Guardant Health 3, Caris Life Sciences 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGHCAIGRALLeader
Larger companyMarket capitalisation $19.56B $6.10B $5.04B GH
Cheaper on earningsLower P/E, profitable companies only -40.3x 63.5x -12.4x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 230.4x — –
Faster revenue growthRevenue growth, trailing twelve months +41.7% +61.5% +12.3% CAI
More profitableNet margin, trailing twelve months -37.9% 9.2% -255.1% CAI
Better return on capitalReturn on invested capital — 13.7% — –
Less leveragedLower net debt / EBITDA — -2.3x — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +61.2% -5.2% +39.3% GH
Better 5-year returnAnnualised price return, 5 years +7.9%/yr — — –
Less volatileAnnualised volatility, 1 year 53.0% 71.8% 112.9% GH
Higher overall scoreMean of the five percentile scores vs peers 27/100 66/100 38/100 CAI

Percentile Scorecard

GHCAIGRAL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGHCAIGRAL
Valuation 15 #84 of 99 25 #75 of 99 5 #94 of 99
Growth 44 #50 of 89 99 #2 of 89 42 #52 of 89
Profitability 9 #84 of 92 70 #28 of 92 6 #87 of 92
Financial Health 54 #48 of 103 81 #20 of 103 100 #1 of 103
Shareholder Returns 13 #55 of 63 55 #29 of 63 –
Overall 27 66 38
  • GH ranked among 103 companies in Healthcare Providers
  • CAI ranked among 103 companies in Healthcare Providers
  • GRAL ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGHCAIGRALSPY
1 month -6.9%-23.8%-17.0% -2.0%
3 months -3.5%+5.7%+70.8% -2.8%
6 months +59.8%+58.4%+94.3% +2.0%
Year to date +48.5%-14.6%+35.4% +10.6%
1 year +61.2%-5.2%+39.3% +12.2%
3 years +519.4%—— +68.1%
3 years, per year +83.7%—— +18.9%
5 years +46.1%—— +61.4%
5 years, per year +7.9%—— +10.1%

Risk

MeasureGHCAIGRALSPY
Volatility, 1Y 53.0%71.8%112.9% 13.6%
Downside volatility, 1Y 50.7%74.4%129.8% 13.9%
Beta vs S&P 500, 1Y 1.321.922.90 1.00
Return / volatility, 1Y 1.15-0.070.35 0.90
Max drawdown, 5Y -85.0%-63.0%-62.9% -25.4%
From 52-week high -19.0%-36.2%-27.1% -3.2%
52-week high $187.22$36.14$158.92 $779.14
52-week low $78.60$14.55$43.03 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGHCAIGRAL
P/E now vs peer median -42.0xmedian 22.4x 68.1xmedian 22.4x -13.3xmedian 22.4x
P/S now vs peer median 16.0xmedian 1.3x 6.3xmedian 1.3x 32.6xmedian 1.3x
EV/EBITDA now vs peer median -40.6xmedian 14.2x 37.5xmedian 14.2x -9.8xmedian 14.2x
P/FCF now vs peer median -88.0xmedian 19.0x 228.5xmedian 19.0x -16.6xmedian 19.0x
P/B now vs peer median -74.1xmedian 2.6x 10.3xmedian 2.6x 2.1xmedian 2.6x
PEG now vs peer median -72.47median 0.84 —median 0.84 —median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGHCAIGRAL
Revenue $1.28B $1.05B $159.20M
Gross profit $833.70M $724.14M $75.17M
Operating income -$504.04M $139.94M -$578.58M
Net income -$485.07M $96.06M -$406.18M
Free cash flow -$232.15M $28.91M -$312.00M
R&D $386.67M $129.36M $188.17M
EPS (diluted) $-3.61 $0.33 $-8.68
Cash & equivalents $1.03B $665.32M $29.00M
Total debt – $393.27M –
Shares (diluted) 134.42M 295.14M 46.78M
Enterprise value $15.17B $2.92B $1.66B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGHCAIGRAL
P/E -42.0x 68.1x -13.3x
P/FCF -88.0x 228.5x -16.6x
P/Operating cash flow -117.8x 78.7x -16.9x
P/S 16.0x 6.3x 32.6x
P/B -74.1x 10.3x 2.1x
P/Tangible book -67.9x 10.3x 7.3x
EV/EBITDA -40.6x 37.5x -9.8x
EV/EBIT -38.5x 44.5x -7.6x
EV/Revenue 15.2x 5.9x 27.6x
EV/FCF -83.6x 215.6x -14.1x
EV/Operating cash flow -111.9x 74.3x -14.4x
PEG (3Y EPS CAGR) -72.47 – –

Growth

14 metrics
MetricGHCAIGRAL
Revenue growth (1Y) 41.7% 61.5% 12.3%
Revenue CAGR (3Y) 33.6% – –
Gross profit growth (1Y) 44.9% 86.2% 13.1%
Gross profit CAGR (3Y) – – –
Operating income growth (1Y) -13.9% 274.2% -0.7%
Operating income CAGR (3Y) 0.6% – –
Net income growth (1Y) -21.6% 151.4% 0.0%
Net income CAGR (3Y) -3.9% – –
EPS growth (1Y) -12.9% 114.2% 22.8%
EPS CAGR (3Y) 0.6% – –
Operating cash flow growth (1Y) 22.2% 15,464% 6.8%
Operating cash flow CAGR (3Y) 19.9% – –
Free cash flow growth (1Y) 11.5% 306.4% 5.4%
Free cash flow CAGR (3Y) 13.9% – –

Profitability

14 metrics
MetricGHCAIGRAL
Gross margin 65.2% 69.1% 47.2%
EBITDA margin -37.4% 15.9% -282.4%
Operating margin -39.4% 13.4% -363.4%
Pretax margin -38.0% 9.3% -344.3%
Net margin -37.9% 9.2% -255.1%
FCF margin -18.2% 2.8% -196.0%
Operating cash flow margin -13.6% 8.0% -192.4%
Return on equity – 15.5% -16.3%
Return on assets -25.5% 7.7% -14.6%
Return on invested capital – 13.7% –
Return on capital employed -33.0% 12.9% -21.5%
Asset turnover 0.7x 0.8x 0.1x
Cash conversion (OCF / net income) 0.4x 0.9x 0.8x
Stock comp / revenue 16.5% 6.7% 40.3%

Financial Health

11 metrics
MetricGHCAIGRAL
Debt / assets – 31.3% –
Debt / equity – 0.6x –
Net debt / EBITDA – -2.3x –
Debt / FCF – 13.6x –
Liabilities / assets 114.6% 49.1% 10.1%
Equity / assets -14.6% 50.9% 89.9%
Interest coverage -96.6x 3.3x –
Current ratio 3.6x 6.7x 8.9x
Quick ratio 3.3x 5.7x 8.6x
Cash ratio 2.8x 4.8x 8.4x
Altman Z-score 3.60 5.68 5.53

Shareholder Returns

7 metrics
MetricGHCAIGRAL
Dividend yield – – –
Net buyback yield -2.0% 0.0% –
Shareholder yield -2.0% 0.0% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGHCAIGRAL
Forward P/E – 230.4xFY2026 –
EPS, next fiscal year $-3.46FY2026 $0.10FY2026 $-9.16FY2026
EPS growth, the year after – +190.0% –
Revenue, next fiscal year $1.43BFY2026 $1.07BFY2026 $158.71MFY2026
Revenue growth, next FY +45.5%FY2026 +31.4%FY2026 +7.8%FY2026
Revenue growth, the year after +26.0% +22.4% +37.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGHCAIGRAL
Held by institutions 100.0% 52.0% 85.4%
Institutions holding 597 246 374
Change in shares held, QoQ -2.5% -6.3% +8.4%
Institutions buying 356 174 183
Institutions selling 180 47 101
Buyers to sellers 1.98 3.70 1.81

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GHCAIGRAL
GH 1.00 0.49 0.46
CAI 0.49 1.00 0.40
GRAL 0.46 0.40 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GH, CAI and GRAL?

Guardant Health (GH) is the largest by market capitalisation: Guardant Health (GH) $19.56B, Caris Life Sciences (CAI) $6.10B, Grail (GRAL) $5.04B.

Which company is growing faster?

Caris Life Sciences (CAI) grew revenue fastest over the trailing twelve months: Guardant Health (GH) +41.7%, Caris Life Sciences (CAI) +61.5%, Grail (GRAL) +12.3%.

Which company is more profitable?

Caris Life Sciences (CAI) has the highest net margin (Guardant Health (GH) -37.9%, Caris Life Sciences (CAI) 9.2%, Grail (GRAL) -255.1%).

Which stock has performed better?

Over the past year Guardant Health (GH) returned the most: Guardant Health (GH) +61.2%, Caris Life Sciences (CAI) -5.2%, Grail (GRAL) +39.3%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Guardant Health (GH) has been the steadiest (Guardant Health (GH) 53.0%, Caris Life Sciences (CAI) 71.8%, Grail (GRAL) 112.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GH, CAI and GRAL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Guardant Health (GH) leads on 3. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.